新的靶向治疗和治疗宫颈癌、子宫内膜癌和卵巢癌的联合治疗方案：年度回顾。
New Targeted Therapies and Combinations of Treatments for Cervical, Endometrial, and Ovarian Cancers: A Year in Review.
机构信息
Department of Oncology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Department of Medical Oncology, University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania.
出版信息
Curr Oncol. 2022 Apr 17;29(4):2835-2847. doi: 10.3390/curroncol29040231.
Abstract
This review of the meaningful data from 2021 on cervical, endometrial, and ovarian cancers aims to provide an update of the most clinically relevant studies presented at important oncologic congresses during the year (the American Society of Clinical Oncology (ASCO) Annual Meeting, the European Society for Medical Oncology (ESMO) Congress and the Society of Gynecologic Oncology (SGO) Annual Meeting). Despite the underlying existence of the COVID-19 pandemic, the last year has been notable in terms of research, with significant and promising advances in gynecological malignancies. Several major studies reporting the effects of innovative therapies for patients with cervical, endometrial, and ovarian cancers might change the medical practice in the future.
摘要
这篇综述回顾了 2021 年关于宫颈癌、子宫内膜癌和卵巢癌的有意义数据，旨在提供在当年重要肿瘤学会议（美国临床肿瘤学会（ASCO）年会、欧洲肿瘤内科学会（ESMO）大会和妇科肿瘤学会（SGO）年会）上展示的最具临床相关性的研究的最新信息。尽管存在 COVID-19 大流行，但过去一年在妇科恶性肿瘤的研究方面取得了显著而有前景的进展。一些重要的研究报告了创新疗法对宫颈癌、子宫内膜癌和卵巢癌患者的影响，这些研究可能会改变未来的医疗实践。
相似文献
1
New Targeted Therapies and Combinations of Treatments for Cervical, Endometrial, and Ovarian Cancers: A Year in Review.
Curr Oncol. 2022 Apr 17;29(4):2835-2847. doi: 10.3390/curroncol29040231.
2
Annual Report of the Committee on Gynecologic Oncology, Japan Society of Obstetrics and Gynecology: Patient Annual Report for 2014 and Treatment Annual Report for 2009.
J Obstet Gynaecol Res. 2017 Nov;43(11):1667-1677. doi: 10.1111/jog.13450. Epub 2017 Sep 11.
3
Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patients report for 2015 and annual treatment report for 2010.
J Obstet Gynaecol Res. 2019 Feb;45(2):289-298. doi: 10.1111/jog.13863. Epub 2018 Nov 13.
4
Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2019 and annual treatment report for 2014.
J Obstet Gynaecol Res. 2022 Jul;48(7):1570-1579. doi: 10.1111/jog.15284. Epub 2022 May 27.
5
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2020 and Annual Treatment Report for 2015.
J Obstet Gynaecol Res. 2023 Nov;49(11):2584-2592. doi: 10.1111/jog.15767. Epub 2023 Aug 21.
6
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2017 and annual treatment report for 2012.
J Obstet Gynaecol Res. 2021 May;47(5):1631-1642. doi: 10.1111/jog.14724. Epub 2021 Feb 25.
7
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2018 and Annual Treatment Report for 2013.
J Obstet Gynaecol Res. 2022 Mar;48(3):541-552. doi: 10.1111/jog.15134. Epub 2022 Jan 13.
8
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology.
J Obstet Gynaecol Res. 2015 Feb;41(2):167-77. doi: 10.1111/jog.12596. Epub 2014 Nov 5.
9
New horizons for platinum-resistant ovarian cancer: insights from the 2023 American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) Annual Meetings.
Int J Gynecol Cancer. 2024 May 6;34(5):760-772. doi: 10.1136/ijgc-2023-004927.
10
Change in practice in gynecologic oncology during the COVID-19 pandemic: a social media survey.
Int J Gynecol Cancer. 2020 Aug;30(8):1101-1107. doi: 10.1136/ijgc-2020-001585. Epub 2020 Jun 7.
引用本文的文献
1
Genome Editing in Gynecological Oncology: The Emerging Role of CRISPR/Cas9 in Precision Cancer Therapy.
Ther Innov Regul Sci. 2025 May 20. doi: 10.1007/s43441-025-00807-w.
2
Shared decision-making in patients with gynecological cancer and healthcare professionals: a cross-sectional observational study in Japan.
J Gynecol Oncol. 2025 May;36(3):e47. doi: 10.3802/jgo.2025.36.e47. Epub 2024 Nov 19.
3
Triage performance of PAX1/JAM3 in opportunistic cervical cancer screening of non‒16/18 human papillomavirus-positive women: a multicenter prospective study in China.
Clin Epigenetics. 2024 Aug 16;16(1):108. doi: 10.1186/s13148-024-01731-w.
4
SIM2: Its Prognostic Significance and Oncogenic Role in Endometrial Carcinoma.
Onco Targets Ther. 2024 Jan 26;17:45-61. doi: 10.2147/OTT.S440788. eCollection 2024.
5
A prognostic model for ovarian neoplasms established by an integrated analysis of 1580 transcriptomic profiles.
Sci Rep. 2023 Nov 8;13(1):19429. doi: 10.1038/s41598-023-45410-x.
6
Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer.
Int J Mol Sci. 2023 Aug 3;24(15):12375. doi: 10.3390/ijms241512375.
7
Identification of Gαi3 as a novel molecular therapeutic target of cervical cancer.
Int J Biol Sci. 2022 Sep 6;18(15):5667-5680. doi: 10.7150/ijbs.77126. eCollection 2022.
本文引用的文献
1
BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer.
Tumori. 2023 Apr;109(2):244-248. doi: 10.1177/03008916211073621. Epub 2022 Mar 20.
2
Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial.
J Clin Oncol. 2021 Nov 20;39(33):3682-3692. doi: 10.1200/JCO.20.02530. Epub 2021 Sep 10.
3
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Lancet Oncol. 2021 Sep;22(9):1275-1289. doi: 10.1016/S1470-2045(21)00342-9. Epub 2021 Aug 4.
4
COVID-19 impact on screening test volume through the National Breast and Cervical Cancer early detection program, January-June 2020, in the United States.
Prev Med. 2021 Oct;151:106559. doi: 10.1016/j.ypmed.2021.106559. Epub 2021 Jun 30.
5
Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline.
JCO Glob Oncol. 2021 Jun;7:1032-1066. doi: 10.1200/GO.21.00085.
6
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Lancet Oncol. 2021 Jul;22(7):1034-1046. doi: 10.1016/S1470-2045(21)00216-3. Epub 2021 Jun 15.
7
Effect of a Randomized, Controlled Trial on Surgery for Cervical Cancer.
N Engl J Med. 2021 Apr 29;384(17):1669-1671. doi: 10.1056/NEJMc2035819.
8
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
J Clin Oncol. 2021 Jun 10;39(17):1842-1855. doi: 10.1200/JCO.21.00306. Epub 2021 Apr 23.
9
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol. 2021 May;22(5):609-619. doi: 10.1016/S1470-2045(21)00056-5. Epub 2021 Apr 9.
10
Genetic variation in cervical preinvasive and invasive disease: a genome-wide association study.
Lancet Oncol. 2021 Apr;22(4):548-557. doi: 10.1016/S1470-2045(21)00028-0.
Zotero 插件